⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 21, 2024Cancer Biotherapy and Radiopharmaceuticals

Immune Response to Molecular Radiotherapy with ¹⁷⁷Lu-DOTATOC: Predictive Value of Blood Cell Counts for Therapy Outcome

Andreas Kluge Richard P. Baum Norman Bitterlich Harshad Kulkarni Ulrike Schorr-Neufing Cees J. A. van Echteld

View at Publisher

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

In a prior, retrospective study, 76% of patients with advanced neuroendocrine tumors undergoing

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kluge et al. (2024) studied this question.

synapsesocial.com/papers/68e63d09b6db6435875ce94b https://doi.org/10.1089/cbr.2024.0031

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Elevated Baseline Mean Corpuscular Volume Predicts the Development of Severe Hematologic Toxicity After<sup>177</sup>Lu-DOTATATE Therapy2024 · 4 citations
2Blood-based transcriptomic biomarkers for response to [177Lu]Lu-DOTA-TATE therapy in neuroendocrine tumors2025
3Cumulative Absorbed Dose and Successive Cyclic Reduction in Absorbed Dose Predict Response to <sup>177</sup> Lu-DOTATATE in Neuroendocrine TumorsOriginal Research · 2026 · 1 citations
4Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [<sup>177</sup>Lu]Lu-DOTATATE2024 · 38 citations
5Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [<sup>177</sup>Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine2024 · 60 citations